Tribune Content Agency on MSN
Mayo Clinic Q&A: Minimally invasive options use energy to treat enlarged prostate
I’m a 64-year-old man who was recently diagnosed with an enlarged prostate after experiencing issues with frequent urination, ...
The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...
Researchers say a new drug-delivery implant could help patients with hard-to-treat bladder cancer avoid losing their bladders — and stay cancer-free for years.
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, ...
The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
Welltica+ on MSN
Tiny implant eliminates bladder cancer in 82% of patients
A new slow-release implant has shown unprecedented success in wiping out bladder cancer in more than 80 percent of patients, ...
Engene Holdings Inc.’s protocol amendment to its phase II trial with detalimogene voraplasmid in bladder cancer worked out in ...
By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Managed Care have been published. According to news reporting originating in Providence, Rhode Island, by NewsRx ...
The robust 77.8% three-month CR rate observed in the UTOPIA trial is highly encouraging and reinforces the potential of UGN-103 to deliver meaningful benefits to patients,” said Liz Barrett, President ...
Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to ...
Q3 2025 Earnings Call November 6, 2025 8:00 AM ESTCompany ParticipantsAndrew Barnett - Head of Investor RelationsPascal Soriot - ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback